Head-to-head · free
KITZ CORPORATION vs Pfizer
6498.T vs PFE — return on capital, cash generation, margins and balance sheet side by side.
6498.T
3 / 3
measures where 6498.T leads
PFE
0 / 3
measures where PFE leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | 6498.T · FY2025 | PFE · FY2025 |
|---|---|---|
| Revenue | $176.7B | $62.6B |
| Net income | $11.5B | $7.8B |
| Revenue growth (yearly, multi-year) | 2.7% | -6.3% |
| Free cash flow | — | $9.1B |
| Free cash flow margin | — | 14.5% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | — | 8.9% |
| Gross margin | — | 74.3% |
| Operating margin | — | 27.8% |
| Net debt / EBITDA | — | 4.23x |
Figures are as reported by each company; latest fiscal year shown.
Where KITZ CORPORATION's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Pfizer's cash went (FY2025)
- Capital spending
- $2.6B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free